The Platform Trial Takeover: Neurology’s Last Best Chance to Stop Failing Patients
Multi-arm multi-stage platform trials could cut neurodegenerative drug timelines in half—but FDA adaptive design rules haven't caught up with...
Immatics’ Anzu-cel Shows 56% Response Rate in Melanoma Phase 1b
Immatics' Anzu-cel demonstrates 56% response rate in melanoma Phase 1b, with 67% efficacy in uveal melanoma and median duration...
Daraxonrasib Halves Death Risk in Phase 3 Pancreatic Cancer Trial
Daraxonrasib halves death risk in Phase 3 pancreatic cancer trial, doubling median overall survival in previously treated metastatic disease.
Apalutamide Plus Hormone Therapy Cuts Prostate Cancer Metastasis Risk by 20%
Apalutamide plus hormone therapy reduced metastasis risk by 20% in high-risk prostate cancer, with nearly ninefold improvement in pathologic...
FDA Accepts NDA for Roche’s Giredestrant in Early-Stage Breast Cancer
FDA accepts NDA for Roche's Giredestrant in early-stage breast cancer, showing 30% reduction in recurrence or death versus standard...
The Data Is Already There. The Question Is Whether You Can See It
A Vanguard Publications Q&A with Naomi, eClinical Solutions.
The Tobacco Exclusion That’s Distorting Every Psychosis-Prevention Trial You’re Running
CHR-P patients smoke at 4.8x the rate of healthy controls. New NAPLS2 neuroimaging data shows why—and why your trial's...
ADHD Dosing Has Two Failure Modes, and Trials Are Designed to Miss Both
A Lancet Psychiatry network meta-analysis of ADHD pharmacotherapy exposes therapeutic inertia and uncritical dose escalation as twin hazards—with direct…
When Your CRO’s Books Were Wrong, Your Trial Budget Probably Was Too
ICON's $158M revenue restatement across 2023–2024 exposes how CRO accounting gaps cascade into site payment delays, contract disputes, and...
Platform Trials Are Neurology’s Best Bet — So Why Is the FDA Still Treating Them Like Experiments?
The Lancet calls MAMS platform trials the fix for neurodegenerative drug failure. With 182 Alzheimer's trials active in 2025,...